standard of care | pharmaphorum

Skip to main content

Saturday 15 August 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

standard of care

Oncology

Prostate Cancer Awareness blue ribbon on blue background

Current and future standard of care in prostate cancer

Despite recent advancements in the field of prostate cancer treatment, there remain distinct gaps in the current standard of care needing improvement.

Digital

chronic wounds

AI in wound: Delivering advanced care through a national wou...

In the UK, one in 50 adults is living with a chronic wound,1 leading to more than £8 billion in healthcare costs in 2017/2018.2 However, these numbers are likely to be

Home

schizophrenia

Considering a new standard of care in schizophrenia

As a psychiatrist, I have observed that schizophrenia is a widely known, but poorly understood mental health condition.

R&D

Making a difference for traumatic brain injury patients

Making a difference for traumatic brain injury patients

TBI is the leading cause of death and disability in young adults in the developed world.

Editor's Picks

Trump order upturns federal childhood vaccines policy

Novo Nordisk partners Amazon on London AI hub

England close to eliminating hep C thanks to treatment drive

Lilly, PTC snap up bankrupt Sangamo's main assets

Definium chalks up new phase 3 win for LSD-based therapy

News

Vogenx surpasses expectations with $81M IPO

Vogenx surpasses expectations with $81M IPO

With $81.3 million raised, Vogenx is the latest in a staggering summer of biotech IPOs. But the queue past this point looks thin.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company